Simbrinza generic
Simbrinza is an ophthalmic drug, available in suspension/drops dosage form, owned by Alcon Labs Inc. This drug, containing active ingredients Brimonidine Tartrate and Brinzolamide, was given market authorization on 19 April, 2013. Simbrinza is patented under two patents, with none of its patents yet expired.
When will Simbrinza generic be available?
Simbrinza holds two patents, with the last one set to expire on 30 October, 2030. This expiry date sets the stage for the release of Simbrinza generic. The details mentioned are not due to Para IV filings but due to patent expiry dates. The general availability of Simbrinza generic is predicted to be possible after 30 October, 2030.
Simbrinza uses
Simbrinza is primarily used to treat elevated intraocular pressure (IOP) in patients with ocular hypertension or open-angle glaucoma. The combined action of Brimonidine, an alpha-2 adrenergic receptor agonist, and Brinzolamide, a carbonic anhydrase inhibitor, decreases fluid production within the eye, thereby reducing IOP.
Simbrinza patent expiration
Two patents protect Simbrinza, none of which has expired. These patents are US9421265 titled 'Aqueous pharmaceutical compositions containing borate-polyol complexes' scheduled to expire on 17 June, 2030, and US9044484 of the same title due to expire on 30 October, 2030. Simbrinza generic release would follow post these expiry dates. Below are the details of the patent: